Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.30M | 12.04M | 10.27M | 10.28M | 9.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.30M | 12.04M | 10.27M | 10.28M | 9.08M |
| Cost of Revenue | 4.79M | 4.61M | 4.20M | 4.15M | 4.12M |
| Gross Profit | 7.51M | 7.43M | 6.07M | 6.14M | 4.95M |
| SG&A Expenses | 5.40M | 5.03M | 5.06M | 4.64M | 4.62M |
| Depreciation & Amortization | -- | -- | -- | 27.00K | 199.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.39M | 9.79M | 9.40M | 8.96M | 9.09M |
| Operating Income | 1.91M | 2.26M | 874.00K | 1.32M | -16.00K |
| Income Before Tax | 1.37M | 2.14M | 576.00K | 820.00K | -524.00K |
| Income Tax Expenses | 4.00K | 4.00K | 4.00K | 5.00K | 4.00K |
| Earnings from Continuing Operations | 1.36M | 2.14M | 572.00K | 815.00K | -528.00K |
| Earnings from Discontinued Operations | -82.00K | -74.00K | -104.00K | 75.00K | -86.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.28M | 2.06M | 468.00K | 890.00K | -614.00K |
| EBIT | 1.91M | 2.26M | 874.00K | 1.32M | -16.00K |
| EBITDA | 1.99M | 2.32M | 926.00K | 1.39M | 224.00K |
| EPS Basic | 0.29 | 0.47 | 0.11 | 0.21 | -0.14 |
| Normalized Basic EPS | 0.19 | 0.31 | 0.08 | 0.12 | -0.08 |
| EPS Diluted | 0.29 | 0.47 | 0.11 | 0.20 | -0.14 |
| Normalized Diluted EPS | 0.19 | 0.30 | 0.08 | 0.12 | -0.08 |
| Average Basic Shares Outstanding | 4.39M | 4.38M | 4.37M | 4.33M | 4.32M |
| Average Diluted Shares Outstanding | 4.42M | 4.40M | 4.38M | 4.34M | 4.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
